UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 2, 2011
IDENIX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 000-49839 | 45-0478605 | ||
(State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
60 Hampshire Street Cambridge, MA | 02139 | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code:(617) 995-9800
(Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Nominee | For | Withheld | Non-Votes | |||||||||
Charles W. Cramb | 56,191,368 | 148,116 | 6,613,368 | |||||||||
Wayne T. Hockmeyer, Ph.D. | 56,189,968 | 149,516 | 6,613,368 | |||||||||
Thomas R. Hodgson | 56,189,968 | 149,516 | 6,613,368 | |||||||||
Tamar D. Howson | 56,110,383 | 229,101 | 6,613,368 | |||||||||
Robert E. Pelzer | 56,146,344 | 193,140 | 6,613,368 | |||||||||
Denise Pollard-Knight, Ph.D. | 56,192,480 | 147,004 | 6,613,368 | |||||||||
Ronald C. Renaud, Jr. | 56,149,796 | 189,688 | 6,613,368 | |||||||||
Anthony Rosenberg | 56,146,444 | 193,040 | 6,613,368 |
For: | 59,752,510 | |||
Against: | 3,182,691 | |||
Abstain: | 17,651 |
For: | 62,765,850 | |||
Against: | 167,747 | |||
Abstain: | 19,255 |
For: | 56,232,199 | |||
Against: | 97,272 | |||
Abstain: | 10,013 | |||
Non Votes: | 6,613,368 |
e) | The frequency of the advisory vote on the compensation of the Company’s named executive officers was approved on an advisory basis for a frequency of every 3 years as follows: |
1 Year: | 18,209,714 | |||
2 Years: | 137,556 | |||
3 Years: | 37,982,136 | |||
Abstain | 10,078 | |||
Non Votes: | 6,613,368 |
IDENIX PHARMACEUTICALS, INC. | ||||
Date: June 6, 2011 | By: | /s/ Maria D. Stahl | ||
Maria D. Stahl | ||||
Senior Vice President and General Counsel | ||||